美沙酮与丁丙诺啡/纳洛酮随机临床试验中生化验证戒断的药物遗传学研究
本研究在阿片使用障碍患者中随机分配至美沙酮或丁丙诺啡/纳洛酮治疗24周,检测美沙酮代谢、丁丙诺啡代谢及μ阿片受体相关基因变异与非治疗阿片类尿液筛查阴性的关联。美沙酮组中OPRM1 rs1799971 AA基因型与更多阿片阴性尿筛查相关,其他基因变异未见显著关联。
要点
- OPRM1 rs1799971 AA基因型美沙酮治疗者阿片阴性尿筛查率更高(IRR=5.24)。
- 该关联在24周纵向分析中基因型×时间交互显著(β=-0.28)。
- 代谢酶基因变异与阿片阴性尿筛查无显著关联。
核心结论
- OPRM1 rs1799971 G基因型携带者可能对美沙酮维持治疗反应较差,该效应持续至24周治疗。
研究设计与样本
- 随机临床试验(NCT03033732),阿片使用障碍患者随机接受美沙酮或丁丙诺啡/纳洛酮治疗24周。
- 每两周收集尿液共12次访视,检测非治疗阿片类,并对CYP2B6、CYP2C19、CYP3A4、UGT2B7和OPRM1基因分型。
- 主要分析聚焦于白种人受试者治疗最后12周(6次访视,滴定后)的数据。
主要发现
- 美沙酮组(n=52)中,OPRM1 rs1799971 AA基因型(对比G基因型)与更多阿片阴性尿筛查相关(IRR=5.24,95%CI=2.43-11.26,P=0.000023)。
- 纵向分析显示全24周(12次访视)基因型×时间交互显著(β=-0.28,95%CI=-0.45至-0.11,P=0.0015)。
- 探索性分析提示OPRM1 rs1799971基因型可能影响治疗保留。
- 其他遗传变异(包括代谢相关变异)与美沙酮或丁丙诺啡/纳洛酮组的阿片阴性尿筛查无显著关联证据。
关键数值与推荐
- OPRM1 rs1799971 AA基因型(对比G基因型)与美沙酮治疗者阿片阴性尿筛查的IRR=5.24(95%CI 2.43-11.26,P=0.000023)。
- 全24周纵向分析基因型×时间交互β=-0.28(95%CI -0.45至-0.11,P=0.0015)。
临床怎么用
- 对于美沙酮维持治疗患者,OPRM1 rs1799971 G基因型可能提示反应较差,可考虑加强监测或个体化治疗策略。
局限性
- 主要分析仅限白种人受试者,样本量较小(美沙酮组n=52)。
- 探索性分析提示OPRM1对治疗保留的影响需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Methadone and buprenorphine/naloxone are opioid agonist therapies for opioid use disorder treatment. Genetic factors contribute to individual differences in opioid response; however, little is known regarding genetic associations with clinical outcomes in people receiving opioid agonist therapies. Participants diagnosed with opioid use disorder, principally consisting of prescription opioids (licit or illicit), were randomized to methadone or buprenorphine/naloxone for 24 weeks of daily treatment (NCT03033732). Urine was collected at 12 biweekly study visits and analyzed for non-treatment opioids. Variants in genes involved in methadone metabolism (CYP2B6, CYP2C19, and CYP3A4), buprenorphine metabolism (CYP3A4 and UGT2B7), and μ-opioid receptor function (OPRM1) were genotyped and analyzed for their association with the number of non-treatment opioid-free urine screens. Primary analyses focused on the last 12 weeks (6 study visits, post-titration) of treatment among those reporting White ethnicity. Additional sensitivity and exploratory analyses were performed. Among methadone-treated participants (n = 52), the OPRM1 rs1799971 AA genotype (vs. G-genotypes, i.e., having one or two G alleles) was associated with greater opioid-free urine screens (incidence rate ratio = 5.24, 95% confidence interval (CI) = 2.43-11.26, P = 0.000023); longitudinal analyses showed a significant genotype-by-time interaction over the full 24 weeks (12 study visits, β = -0.28, 95% CI = -0.45 to -0.11, P = 0.0015). Exploratory analyses suggest an OPRM1 rs1799971 genotype effect on retention. No evidence of association was found between other genetic variants, including in metabolic variants, and non-treatment opioid-free urine screens in the methadone or buprenorphine/naloxone arms. Those with the OPRM1 rs1799971 G-genotypes may have a poorer response to methadone maintenance treatment, an effect that persisted through 24 weeks of treatment.
引用
- Kazi I, Chenoweth MJ, Jutras-Aswad D, et al. Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone. Clin Pharmacol Ther. 2023. PMID: 38009933. doi:10.1002/cpt.3112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。